
On Saturday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released new Phase 3 PEGASUS study results on Saturday.
The data show that its therapy Palynziq (pegvaliase-pqpz) significantly reduced blood phenylalanine (Phe) levels in adolescents with phenylketonuria (PKU), a rare metabolic disorder.